FDA Outreach To Physicians On LABAs Shows Challenges Of Safety Strategy
Executive Summary
FDA appears to have settled on a mechanism for explaining its policy decisions to the physician community: publishing articles in The New England Journal of Medicine. Whether the strategy can produce the desired results remains less clear
You may also be interested in...
Foradil Completes LABAs’ Exit From Risk Evaluation and Mitigation Strategies
FDA says Novartis’ assessment of the long-acting beta agonist’s REMS, which consisted only of a communication plan, shows the “plan, and therefore the REMS, has met its goal.”
Ultrasound Contrast Agents Should Drop Boxed Warning, Medical Society Tells FDA
Citizen petition by the International Contrast Ultrasound Society says updated safety data from recent meta-analysis makes black box unnecessary.
FDA Supersizes Its Order For LABA Safety Studies
The trials, which follow a label change and new REMS, will encompass seven times the patients included in the studies submitted to FDA for approval.